Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide

References

• Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349–e356. doi:10.1016/S2352-3018(17)30066-8
   PubMed Web of Science ®Google Scholar
• Li Z, Purcell DW, Sansom SL, Hayes D, Hall HI. Vital signs: HIV transmission along the continuum of care - United States, 2016. MMWR Morb Mortal Wkly Rep. 2019;68(11):267–272. doi:10.15585/mmwr.mm6811e1
   PubMed Web of Science ®Google Scholar
• HIV Care Continuum. What does the HIV care continuum show? 2020. Available from: https://www.hiv.gov/federal-response/policies-issues/hiv-aids-care-continuum. Accessed May 13, 2020.
   Google Scholar
• Ryan White HIV/AIDS Program. Annual Client-Level Data Report. 2018.
   Google Scholar
• Kangethe A, Polson M, Lord TC, Evangelatos T, Oglesby A. Real-world health plan data analysis: key trends in medication adherence and overall costs in patients with HIV. J Manag Care Spec Pharm. 2019;25(1):88–93.
   PubMed Web of Science ®Google Scholar
• Forstein M, Cournos F, Douaihy A, Goodkin K, Wainberg ML, Wapenyi KH. Guideline Watch: Practice Guidelines for the Treatment of Patients with HIV/AIDS. Arlington, VA: American Psychiatric Association; 2006.
   Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30. doi:10.7326/0003-4819-133-1-200007040-00004
   PubMed Web of Science ®Google Scholar
• Wutoh AK, Elekwachi O, Clarke-Tasker V, Daftary M, Powell NJ, Campusano G. Assessment and predictors of antiretroviral adherence in older HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33(Suppl 2):S106–114. doi:10.1097/00126334-200306012-00007
   Web of Science ®Google Scholar
• Davies G, Koenig LJ, Stratford D, et al. Overview and implementation of an intervention to prevent adherence failure among HIV-infected adults initiating antiretroviral therapy: lessons learned from Project HEART. AIDS Care. 2006;18(8):895–903. doi:10.1080/09540120500329556
   PubMed Web of Science ®Google Scholar
• Pharmacy Quality Alliance. PQA measure overview; 2019. Available from: https://www.pqaalliance.org/assets/Measures/2019_PQA_Measure_Overview.pdf. Accessed April 29, 2020.
   Google Scholar
• Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191(3):339–347. doi:10.1086/427192
   PubMed Web of Science ®Google Scholar
• Meresse M, March L, Kouanfack C, et al. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon. HIV Med. 2014;15(8):478–487. doi:10.1111/hiv.12140
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available from: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/37/whats-new-in-the-guidelines. Accessed January 24, 2020.
   Google Scholar
• US Food and Drug Administration. Prescribing information - SYMTUZA®; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210455s004lbl.pdf. Accessed November 22, 2019.
   Google Scholar
• Beer L, Skarbinski J. Adherence to antiretroviral therapy among HIV-infected adults in the United States. AIDS Educ Prev. 2014;26(6):521–537. doi:10.1521/aeap.2014.26.6.521
   PubMed Web of Science ®Google Scholar
• Kim J, Lee E, Park BJ, Bang JH, Lee JY. Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009–2016: a nationwide study. Sci Rep. 2018;8(1):3133. doi:10.1038/s41598-018-21081-x
   PubMed Web of Science ®Google Scholar
• Simoni JM, Huh D, Wilson IB, et al. Racial/Ethnic disparities in ART adherence in the United States: findings from the MACH14 study. J Acquir Immune Defic Syndr. 2012;60(5):466–472. doi:10.1097/QAI.0b013e31825db0bd
   PubMed Web of Science ®Google Scholar
• Gross IM, Hosek S, Richards MH, Fernandez MI. Predictors and profiles of antiretroviral therapy adherence among african american adolescents and young adult males living with HIV. AIDS Patient Care STDS. 2016;30(7):324–338. doi:10.1089/apc.2015.0351
   Web of Science ®Google Scholar
• Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475–490. doi:10.2147/PPA.S192735
   PubMed Web of Science ®Google Scholar
• Chakraborty A, Qato DM, Awadalla SS, Hershow RC, Dworkin MS. Antiretroviral therapy adherence among treatment-naive HIV-infected patients. AIDS. 2020;34(1):127–137. doi:10.1097/QAD.0000000000002384
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen K, Kalichman SC. Barriers to HIV medication adherence as a function of regimen simplification. Ann Behav Med. 2017;51(1):67–78. doi:10.1007/s12160-016-9827-3
   PubMed Web of Science ®Google Scholar
• Clay PG, Yuet WC, Moecklinghoff CH, et al. A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther. 2018;15(1):17. doi:10.1186/s12981-018-0204-0
   PubMed Web of Science ®Google Scholar
• Hines DM, Ding Y, Wade RL, Beaubrun A, Cohen JP. Treatment adherence and persistence among HIV-1 patients newly starting treatment. Patient Prefer Adherence. 2019;13:1927–1939. doi:10.2147/PPA.S207908
   PubMed Web of Science ®Google Scholar
• Mohd Salleh NA, Richardson L, Kerr T, et al. A longitudinal analysis of daily pill burden and likelihood of optimal adherence to antiretroviral therapy among people living with HIV who use drugs. J Addict Med. 2018;12(4):308–314. doi:10.1097/ADM.0000000000000403
   PubMed Web of Science ®Google Scholar
• Raffi F, Yazdanpanah Y, Fagnani F, Laurendeau C, Lafuma A, Gourmelen J. Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database. J Antimicrob Chemother. 2015;70(7):2121–2128.
   PubMed Web of Science ®Google Scholar
• Sutton SS, Hardin JW, Bramley TJ, D’Souza AO, Bennett CL. Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks. Am J Manag Care. 2016;22(4):242–248.
   PubMed Web of Science ®Google Scholar
• Yager J, Faragon J, McGuey L, et al. Relationship between single tablet antiretroviral regimen and adherence to antiretroviral and non-antiretroviral medications among veterans’ affairs patients with human immunodeficiency virus. AIDS Patient Care STDS. 2017;31(9):370–376. doi:10.1089/apc.2017.0081
   PubMed Web of Science ®Google Scholar
• Cotte L, Ferry T, Pugliese P, et al. Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study. PLoS One. 2017;12(2):e0170661. doi:10.1371/journal.pone.0170661
   PubMed Web of Science ®Google Scholar
• Lewis JM, Smith C, Torkington A, et al. Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: a multicentre retrospective cohort study. J Infect. 2017;74(4):401–407. doi:10.1016/j.jinf.2017.01.012
   Web of Science ®Google Scholar
• Cohen J, Beaubrun A, Bashyal R, Huang A, Li J, Baser O. Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries. AIDS Res Ther. 2020;17(1):12. doi:10.1186/s12981-020-00268-1
   Web of Science ®Google Scholar
• US Department of Health and Human Services. Human research protections: regulations and policy. Available from: www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html#46.101. Accessed July 15, 2020.
   Google Scholar
• American Pharmacists Association. Measuring adherence. Available from: https://www.pharmacist.com/measuring-adherence. Accessed January 24, 2020.
   Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi:10.1093/aje/kwq433
   PubMed Web of Science ®Google Scholar
• Hardy H, Luo D, Israel D, Simonson RB, Dunn K. Treatment adherence and virologic response over 48 weeks among patients rapidly initiating darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in the DIAMOND study [Poster 606]. Presented at: 14th International Conference on HIV Treatment and Prevention Adherence17–19 June 2019; Miami, FL.
   Google Scholar
• Sax PE, Meyers JL, Mugavero M, Davis KL, Ross JS. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012;7(2):e31591. doi:10.1371/journal.pone.0031591
   PubMed Web of Science ®Google Scholar
• Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2019.
   Web of Science ®Google Scholar
• Karam M, Laurence B, Ricky H, et al. Changes in BMI associated with antiretroviral regimens in treatment-experienced, virologically suppressed individuals living with HIV. Presented at: IDWeek2019; Washington, DC.
   Google Scholar
• Kerchberger AM, Sheth AN, Angert CD, et al. Weight gain associated with integrase stand transfer inhibitor use in women. Clin Infect Dis. 2019.
   Web of Science ®Google Scholar
• Norwood J, Turner M, Bofill C, et al. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527–531. doi:10.1097/QAI.0000000000001525
   PubMed Web of Science ®Google Scholar
• Plankey M, Bacchetti P, Jin C, et al. Self-perception of body fat changes and HAART adherence in the women’s interagency HIV study. AIDS Behav. 2009;13(1):53–59. doi:10.1007/s10461-008-9444-7
   PubMed Web of Science ®Google Scholar
• Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. Front Endocrinol (Lausanne). 2018;9:705. doi:10.3389/fendo.2018.00705
   PubMed Web of Science ®Google Scholar
• Cantudo-Cuenca MR, Jimenez-Galan R, Almeida-Gonzalez CV, Morillo-Verdugo R. Concurrent use of comedications reduces adherence to antiretroviral therapy among HIV-infected patients. J Manag Care Spec Pharm. 2014;20(8):844–850.
   Google Scholar
• Centers for Disease Control and Prevention. HIV surveillance report, 2018 (Preliminary); vol. 30; 2019. Available from: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed April 29, 2020.
   Google Scholar